Patient Square, a dedicated health care investment firm, led a $71m series B funding round in Resolve Biosciences, a Molecular Cartography technology company, with participation from EDBI, PS Capital, Alafi Capital, and NRW.BANK. “Spatial biology is widely considered to be the most significant new field in life sciences. With its talented team and proprietary Molecular Cartography technology, Resolve is leading the new era of single-cell spatial analysis and opening the door to a wave of scientific findings that will redefine our understanding of disease and lead to new therapies and improved patient outcomes,” Laura Furmanski, Patient Square Capital Partner.